Shiva Adham, NP
Nurse Practitioner · Reno, NVNPI 1003488214
Payments from drug & device makers
Across 87 payments — averaging $23.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Calliditas Therapeutics US Inc.$326
- AstraZeneca$234
- Boehringer Ingelheim$200
- Novartis$196
- Travere Therapeutics, Inc.$196
- Amgen$176
- plus $713 from 12 others
What the payments were for
- Food & beverage$2,01899%
- Education$221%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Calliditas Therapeutics US Inc. | 18 | $326 |
| AstraZeneca | 11 | $234 |
| Boehringer Ingelheim | 6 | $200 |
| Novartis | 7 | $196 |
| Travere Therapeutics, Inc. | 8 | $196 |
| Amgen | 7 | $176 |
| Otsuka America Pharmaceutical, Inc. | 7 | $166 |
| Ardelyx, Inc. | 6 | $123 |
| ANI Pharmaceuticals, Inc. | 5 | $114 |
| Vifor Pharma, Inc. | 1 | $71 |
| Bayer | 3 | $55 |
| Fresenius USA Marketing, Inc. | 2 | $45 |
| Scpharmaceuticals Inc. | 1 | $35 |
| Recordati_rare_diseases_inc. | 1 | $26 |
| Daiichi Sankyo Inc. | 1 | $23 |
| OPKO Pharmaceuticals, LLC | 1 | $22 |
| Mallinckrodt Hospital Products Inc. | 1 | $17 |
| GSK | 1 | $15 |
How this compares
$2,040 in reported general payments places this provider in the 80th percentile of 933 nurse practitioner providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sevelamer Carbonate | 18 | $13,074 |
| ProsolParenteral Amino Acid 20% No.1 | 26 | $3,686 |
| Cinacalcet Hcl | 28 | $2,730 |
| Calcium Acetate | 14 | $1,973 |
| Calcitriol | 82 | $1,444 |
| Furosemide | 83 | $557 |
| Potassium Chloride | 22 | $546 |
| Allopurinol | 47 | $516 |
| Terazosin Hcl | 19 | $513 |
| Amlodipine Besylate | 53 | $383 |
| Doxazosin Mesylate | 11 | $371 |
| Hydralazine Hcl | 29 | $367 |
| Spironolactone | 17 | $182 |
| Lisinopril | 22 | $157 |
| Carvedilol | 23 | $142 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in Reno
- Melissa DelamoraReno$20K
- Darian ThorpReno$18K
- Mary Beth MedinaReno$11K
- Kristen BowmanReno$10K
- Laura HayReno$8K
- Laura HarshReno$7K
- Mary HelmreichReno$7K
- Rhonda StrunkReno$7K
- Rachael HueftleReno$7K
- Rhonda NavarroReno$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.